chrisvoncsefalvay/vaers-outcomes huggingface dataset:
swollen with little bumps; swollen with little bumps; Injection site hot to touch,; injection site red; Injection site itchy and patchy; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (swollen with little bumps), VACCINATION SITE INDURATION (swollen with little bumps), VACCINATION SITE WARMTH (Injection site hot to touch,), INJECTION SITE ERYTHEMA (injection site red) and VACCINATION SITE PRURITUS (Injection site itchy and patchy) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A,) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE SWELLING (swollen with little bumps), VACCINATION SITE INDURATION (swollen with little bumps), VACCINATION SITE WARMTH (Injection site hot to touch,), INJECTION SITE ERYTHEMA (injection site red) and VACCINATION SITE PRURITUS (Injection site itchy and patchy). At the time of the report, VACCINATION SITE SWELLING (swollen with little bumps), VACCINATION SITE INDURATION (swollen with little bumps), VACCINATION SITE WARMTH (Injection site hot to touch,), INJECTION SITE ERYTHEMA (injection site red) and VACCINATION SITE PRURITUS (Injection site itchy and patchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.        No relevant concomitant medications were reported. No treatment information was provided.
I had a dry cough and a lot of congestion. I was coughing and sneezing.  I had a low grade fever for about 4 to 5 days. I did not take any medication for my symptoms.  I slept for 12 hours a day. My fever lasted for 4-5 days but my cough/sneezing lasted for about two weeks. It has been exactly two months since I tested positive for covid and I am now just feeling like myself again. I feel like I just don't have any taste or smell as of today 3/17/2022.  This in no shape or form in regards to the vaccination or dose 3.
I developed a cough on 9/14 after being exposed to an individual on 9/10 and 9/12 who tested positive for covid on 9/13. I then developed congestion, loss of taste and smell, headache, and fatigue. I tested positive for covid on 9/15 via PCR test.
Redness and swelling that grew to the size of a softball in diameter. The whole circle was hard, bright red, and hot to touch. The doctor's office recommended cold compresses and take Benadryl for the swelling. After two days of doing this, swelling has not gone down and area still feels hard and hot.
Narrative:  Patient is a 79-year-old vaccinated (s/p 2 doses moderna) male with co-morbidities of OSA, T2DM, HTN, HLD and obesity who presents for fatigue and dyspnea with a known positive COVID-19 test from 8/9/2021. Patient is a poor historian but reports his symptoms started around the time of his positive test on 8/9. He states he did not feel short of breath but did have fatigue In the ED, intiially O2 saturation 65% on room air, was placed on HFNC FiO2 32%, now requriing 100% fio2 on hhfnc. Patient was fully vaccinated with COVID vaccine Moderna on 2/11/21 and 3/11/21.
RASH; PAIN; Eczema; This case was reported by a pharmacist via call center representative and described the occurrence of rash in a 63-year-old female patient who received Herpes zoster (Shingrix) (batch number P57AA, expiry date 5th July 2021) for prophylaxis.   On 22nd April 2019, the patient received the 1st dose of Shingrix (intramuscular). In April 2019, 2 days after receiving Shingrix, the patient experienced rash, pain and eczema. On an unknown date, the outcome of the rash, pain and eczema were recovered/resolved.   It was unknown if the reporter considered the rash, pain and eczema to be related to Shingrix.  Additional details were provided as follows: The patient received vaccine in right arm. The patient experienced rash on back and pain at sites where she had eczema. The symptoms begun over the 2-3 days following vaccination. The pain lasted for a few weeks then resolved. The rash lasted for a couple of days but then resolved. The reporter consented to follow up.
PT PRESENTED TO HEALTH DEPT ON 09/21/2023, STATED THAT HER VACCINE REACTION STARTED THE EVENING OF 09/19/2023 INCLUDING REDNESS THE SIZE OF A BASEBALL NOTED AT THE INJECTION SITE, A LINE OF HIVES ALSO NOTED AT INJECTION SITE, SITE WAS HARD AND WARM TO THE TOUCH, PT STATES THAT THE INJECTION SITE ITCHES ALL SYMPTOMS REPORTED ARE STILL PRESENT TODAY 09/21/2023; PT REPORTED THAT ON 09/20/2023 SHE NOTICED A FLARE UP IN HER ASTHMA; PT NOT IS DISTRESS AS OF 09/21/2023; INTRUCTED PT TO CONTACT PCP DR TO SCHEDULE APPT FOR TODAY 09/21/2023, IF PCP IS UNAVAILABLE PT WAS ADVISED TO GO TO WALK IN CARE FOR FURTHER FOLLOW-UP REGARDING REACTION, PT VERBALIZED UNDERSTANDING. INSTRUCTED PT TO PHONE BACK LATER TODAY 09/21/2023 TO UPDATE US ON HER CONDITION; HAVE NOT HEARD UPDATE YET AS OF 1626 ON 09/21/2023.
Information has been received from an office manager referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant medication were not provided. On 30-AUG-2016, the patient was vaccinated with an expired dose of PNEUMOVAX 23 (lot # L001311, expiration date 06-JUL-2016; dose and route were unknown). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Within the first  15 minutes, I had neuropathy of my fingers and toes which lasted about 10 days. When I mentioned the neuropathy to a nurse on-site, they took my blood pressure, the systolic of  which had sky rocketed 70 points. Over the next 30 minutes,  my blood pressure only came down 20 points. The following week, my average blood pressure was 125/73. Shortly after the neuropathy ended, twelve days after receiving the vaccine, the COVID arm rash appeared on my upper left arm, which remained for about a week.
Numbness (feeling of pins and needles) on the right side of the face. Started about 12 hrs after receiving the vaccine and is still continuing today 3 days later. No loss of motion is occurring with the first vaccine. I am concerned about the second vaccine.
had 1st shingles and my 2nd, bit these from Shingles/Suspected Vaccination Failure; bit these from Shingles; fell numbness on Upper right head down to right leg; tiny stroke; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. In FEB-2023, less than 2 months after receiving Shingles vaccine and less than 2 years after receiving Shingles vaccine, the patient experienced stroke (Verbatim: tiny stroke) (serious criteria GSK medically significant) and numbness (Verbatim: fell numbness on Upper right head down to right leg). On an unknown date, the patient experienced vaccination failure (Verbatim: had 1st shingles and my 2nd, bit these from Shingles/Suspected Vaccination Failure) (serious criteria GSK medically significant) and shingles (Verbatim: bit these from Shingles). The outcome of the vaccination failure was unknown and the outcome of the stroke and shingles were not reported and the outcome of the numbness was not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, stroke, shingles and numbness to be related to Shingles vaccine and Shingles vaccine.  It was unknown if the company considered the vaccination failure, stroke, shingles and numbness to be related to Shingles vaccine and Shingles vaccine.   Additional Information: GSK Receipt Date: 12-MAR-2023 This case was reported by a patient via  interactive digital media. The patient had the 1st dose of shingles last year 2022 and his/her 2nd shingles dose in last January or February, he/she forgot the dates. The reporter stated that last February 2023 7.00 pm he/she felt numbness on his/her upper right head down to his/her right body part of his/her right leg.  The patient was to emergency hospital and in doctors diagnosed as tiny stroke. The patient was treated with needles on his/her right arm and CT (Computerised tomogram) and ultrasound found nothing. The patient felt still the numbness if his/her right arm sometimes. The patient stated that he/she bit these from shingles and he/she should not get that shingles shots twice. The patient would ask now how safe was your shingles to our health. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting.  The follow up would not possible as no contact details were available.
Patient experienced fever (tactile, value unknown), emesis, and diarrhea 2-3 days after each set of vaccinations at 2 months, 4 months, and 6 months. The vaccines in common given at these visits were PEDIARIX and PREVNAR. While a fever is a common reaction to these, the GI symptoms of emesis and diarrhea are not typically seen, and therefore, the provider wished to make you aware.
No side effects reported; HCP calling to report AE for patient who received improperly stored PROQUAD on 04OCT2023. No side effects reported. No other medical information known. Operator of Device was a Healthcare Professional. HCP permission to contact obtained. See addition; This spontaneous report was received from a healthcare professional (HCP) and refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 04-OCT-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, lot # X018582 has been confirmed as valid, expiration date: 05-JAN-2025 (dose and route of administration were not provided) administered for prophylaxis. The vaccine underwent temperature excursion that same date, with a minimum temperature of -9.8 degree Celsius in a time frame of 12 minutes (product storage error). No previous temperature excursion and additional side effects were reported (no adverse event).  This is one of 7 reports received from the same reporter.; Sender's Comments:  US-009507513-2310USA007934:
No adverse effects reported.; an unspecified number of patients received improperly stored dose of RECOMBIVAX, GARDASIL 9, MMRII, or PROQUAD; The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify.  Follow-up information has been received from the practice manager on 18-SEP-2018.  This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided.       On 09-AUG-2018, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant Human albumin) (strength and route were unknown) (lot# R006216 and expiration date 28-AUG-2019) for prophylaxis (Incorrect product storage). The sterile diluent (MERCK STERILE DILUENT) was properly stored. No adverse event was reported.  The excursion temperature on 22-SEP-2017, 17-OCT-2017, 06-DEC-2017, 07-DEC-2017, 30-JAN-2018, 23-FEB-2018, 18-MAY-2018, 05-JUL-2018, 15-AUG-2018 was 6 degree Celsius for maximize 8.75 hours. The excursion temperature on 02-MAR-2018, 27-AUG-2018 was 7 degree Celsius for maximize 8.75 hours. The excursion temperature on 07-DEC-2017 was 8 degree Celsius for maximize 15 hours. The call was not because of data logger.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1809USA003709: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001956: US-009507513-1810USA001957: US-009507513-1810USA001959:
pt started crying the afternoon of inj & cried & fussed x 3 days;2 days p/vax had episodes when eyes rolled back & had uncontrolled motion of arms & legs;pt had no fever;pt dec intake of liquids & was irritable for 3 days;seen by MD;
I did get sick with the first one back in the late 50's; Initial information received on 25-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer (Patient) via the agency through social media.  This case involves an unknown gender patient of late 50's who got sick with the first one (illness), while the patient received vaccine Influenza vaccine.  The patient's medical history, past medical treatment(s), concomitant therapy, past vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect Influenza Vaccine produced by unknown manufacturer (lot number and expiry date not reported) via unknown route at an unknown administration site for prophylactic vaccination. There were 3 flu shots given.  On an unknown date (latency: unknown) after starting the suspect vaccine therapy, the patient got sick with the first one (illness) and it hurt like hell.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was unknown.   There will be no information available on batch number for this case.
Developed numbness 4th and 5th digits both hands, accompanied by weakness in both hands 6 weeks after receiving vaccine. Had genetic testing, which showed PMP 22 deletion. Continues to be symptomatic +. Feels SX were caused by vaccine. 01/17/07-Records received and reviewed from PCP also indicated he no longer treats this patient. Office visit 10/10/05-Assessment bilateral numbness in digits four and fifth ulnar nerve root or C8 nerve root distribution. Complaint of bilateral fourth and fifth digit numbness. Numbness has progressed as far as the forearm just short of the elbow. History right shoulder injury which includes a tear of the labrum. Swimmer in high school. Spends significant amount of time on computer. Numbness started in left arm first and then progressed to the right. No pain. Does have neck pain, Grip strength normal, negative Phalen and Tinel sign bilaterally for median nerve.  11/23/05-neuro exam: exam WNL except for decreased grip strength on right. Assessment: neuropathy, poly neuropathy unspecified.  03/12/07-records received from neurologist for DOS 11/28/05 PE:WNL except for motor exam showed mildly weak right hand grip. Mild weakness in left hand grip especially involving the 4th and 5th digist. No atrophy. Characteristic positioning of both hands of mild ulnar weakness. No atrophy no fasciculation. No ataxia. Sensory exam showed mild decreased sensation to pin prick in ulnar nerve territories bilaterally. Hypesthesia did not involve the forearm.  Impression: bilateral ulnar nerve neuropathy. No indication in history of GBS syndrome or CIDP. Other potential causes heavy metal screen, vitamin B12 deficiency level, ESR, ANA and Charcot-Marie Tooth type 1 disease. Per information received from the annual follow up the patient's recovery status is unknown, pt's last visit to office 2/07. Follow-up: Continues to have weakness in both hands and numbness and tingling which comes and goes. EMG with polyneuropathy bilateral upper extremities.
Adacel 0.5 mL IM was given on 07/24/2007.  Patient experienced redness and soreness around injection site.  Patient had negative respiratory S/S 10 X14 cm.  Patient was gieven Benadryl cool compress and symptoms resided.
Initial report was received from a health care professional on 30 November 2011. A female patient had received a subcutaneous injection of YF VAX, sanofi pasteur Inc., (lot number, site and exact date of administration not reported) in September 2011. At 2:00 AM following the vaccination, the patient felt a little achy all over and felt as if they had flu-like symptoms. The patient felt fine later that morning. The patient had no illness at the time of vaccination. It was unknown if the patient took any concomitant medications or had any relevant past medical history. No further information was available at the time of the report. The patient's outcome was reported as recovered. Documents held by sender: None.
Increased sensitivity to cold in fingers; is is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): US-PFIZER INC-2021549622 (Pfizer).  A 42 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 09Apr2021 19:45 (Lot number: EW0158) at the age of 42 years as dose 1, single and administered in arm left, administration date 01May2021 17:45 (Lot number: EW0173) as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LISINOPRIL; TRINTELLIX; ATOMOXETINE HCL. Past drug history included: Indomethacin, reaction(s): "known allergies", notes: known allergies: Indomethacin; Nabumetone, reaction(s): "known allergies", notes: known allergies: Nabumetone. The following information was reported: PERIPHERAL COLDNESS (non-serious) with onset 12Apr2021, outcome "unknown", described as "Increased sensitivity to cold in fingers". Therapeutic measures were not taken as a result of peripheral coldness.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient not has been tested for COVID-19. Device Date is mentioned as 16May2021.  No follow-up attempts are possible. No further information is expected.
Maternal exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy). At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided No treatment information provided; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this XX-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy
Fever of 102.8, chills,  fainting, pain and swelling at injection site, numbness in left arm and left leg, and unable to lift left arm
Patient experienced a marked increase in the intensity of his tinnitus. This began two days after the second dose, and has continued unabated since then.
pain and numbness to left arm, with headache soon after receiving vaccine; took Ibuprofen for achy arm but symptoms lasted for about a week; within 10 days, arm pain resolved but started to feel pressure to chest and nausea with mucosy vomit and overall not feeling well; notices feeling itching to neck without rash when nauseated
PATIENT CAME IN FOR J& J VACCINE  RECEIVED VACCINE AND WENT TO BE SEATED.  UPON SITTING  THE PT BECAME PALE AND WAS SWEATING.  HE BEGAN TO SEE DARK AND FELT FAINT.  I EXPLAINED WHAT WAS HAPPENING AND AND HAD THE PATIENT TRY TO STAY AWAKE AND TALKING.  HIS BLOOD PRESSURE WAS 180/154 WITH PULSE OF 99.  HE FELT NAUSEOUS AND VOMITED. PT STATED THAT HE DID HAVE THIS REACTION OCCUR ONCE BEFORE WHILE DRAWING BLOOD.  HE SAT FOR A FEW MORE MINUTES AND BEGAN TO REGAIN COLOR AND TEMPERATURE WARMED BACK UP AND HE STOPPED SWEATING.  I TOOK HIS BLOOD PRESURE AGAIN AND IT WAS IN NORMAL RANGE. HE FELT FINE AND THEN LEFT.
HEADACHES; HIVES; LIGHTHEADEDNESS; FLUSHED; WARM; BALANCE ISSUES; FATIGUE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's concurrent conditions included: allergy, inflammatory condition, and immune dysregulation. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, and expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On APR-2021, the patient experienced balance issues. On APR-2021, the patient experienced fatigue. On 06-APR-2021, the patient experienced lightheadedness. On 06-APR-2021, the patient experienced flushed. On 06-APR-2021, the patient experienced warm. On 07-APR-2021, the patient experienced hives. On an unspecified date, the patient experienced headaches. Treatment medications (dates unspecified) included: prednisone. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from lightheadedness, balance issues, and fatigue on APR-2021, and hives on 13-APR-2021, was recovering from flushed, and warm, and the outcome of headaches was not reported. This report was non-serious.
Fever (104.4) localized pain, accelerated heart rate, nausea, headache, dizziness
FACE TWO TONED IN COLOR; BIG RED BUMP; LEFT SIDE OF FACE WIGGING OUT/DRY RASH/BUMPS; This spontaneous report received from a patient concerned a 34 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: social drinker, and smoker, and other pre-existing medical conditions included: No previous history of skin problems for past 34 years. No history of drug abuse or illicit drug use. The patient experienced drug allergy when treated with morphine. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1822809, expiry: UNKNOWN) dose was not reported, administered on 07-OCT-2021 for prophylactic vaccination. No concomitant medications were reported. On 09-OCT-2021, the patient experienced face two toned in color. On 09-OCT-2021, the patient experienced big red bump. On 09-OCT-2021, the patient experienced left side of face wigging out/dry rash/bumps. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from big red bump on NOV-2021, had not recovered from left side of face wigging out/dry rash/bumps, and the outcome of face two toned in color was not reported. This report was non-serious.
admitted to hospital 08/04/2021 thru 08/07/21 and diagnosed with pneumonia.  Re-admitted to hospital on 08/09/2021 for worsening symptoms. Currently still in hospital
Pt developed, redness at injection site of flu vax. Left upper arm redness cool compress applied to site. Shortly there after pt complained of swelling of the tongue, with progressive symptoms. Benadryl given in right arm.
Patient received the Pfizer vaccine dose #1 on 09/16. The injection was in the left upper arm in deltoid. Started have symptoms couple hours of vaccination of nausea, which she took Benadryl, arm pain, soreness at injection site, and headache. She has a history of migraines. The patient took Tylenol, had sense of fatigue.
ACUTE HYPOXEMIC RESPIRATORY FAILURE HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 1/24/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Patient got a red welt around the injection site, it was warm and tight, it eventually extended down to the elbow. Arm was very sore.